Liontrust Investment Partners LLP Has $244.02 Million Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Liontrust Investment Partners LLP increased its holdings in Thermo Fisher Scientific by 0.3%, now owning 490,390 shares worth approximately $244 million, making it the firm’s second-largest holding.
• CEO Marc N. Casper sold 10,000 shares recently, reducing his ownership stake in the company by 7.99%, while insiders have sold a total of 18,400 shares in the last quarter.
• Analysts have a consensus rating of "Moderate Buy" for Thermo Fisher Scientific, with an average price target of $593.00, following several upgrades from different financial institutions.

Liontrust Investment Partners LLP boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 490,390 shares of the medical research company's stock after purchasing an additional 1,693 shares during the quarter. Thermo Fisher Scientific comprises about 3.8% of Liontrust Investment Partners LLP's holdings, making the stock its 2nd largest position. Liontrust Investment Partners LLP owned 0.13% of Thermo Fisher Scientific worth $244,018,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Thermo Fisher Scientific by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock valued at $16,659,627,000 after acquiring an additional 230,382 shares during the last quarter. Capital World Investors boosted its stake in shares of Thermo Fisher Scientific by 1.1% during the 4th quarter. Capital World Investors now owns 9,430,120 shares of the medical research company's stock valued at $4,905,812,000 after buying an additional 104,343 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Thermo Fisher Scientific by 13.2% during the 4th quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock valued at $2,034,107,000 after buying an additional 455,004 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in shares of Thermo Fisher Scientific by 86.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock valued at $1,604,338,000 after buying an additional 1,433,444 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Thermo Fisher Scientific by 4.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after purchasing an additional 115,463 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock traded up $4.92 during trading on Friday, reaching $489.96. The company had a trading volume of 2,462,453 shares, compared to its average volume of 3,059,810. The firm's 50 day simple moving average is $434.83 and its two-hundred day simple moving average is $459.02. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The company has a market capitalization of $185.01 billion, a PE ratio of 28.34, a PEG ratio of 2.61 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The firm's revenue was up 2.9% compared to the same quarter last year. During the same period last year, the business earned $5.37 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 8,000 shares of the business's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $454.45, for a total value of $3,635,600.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $52,340,824.30. This represents a 6.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,400 shares of company stock worth $8,345,792 in the last three months. 0.33% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on TMO shares. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Hsbc Global Res cut Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. HSBC reaffirmed a "hold" rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Wells Fargo & Company decreased their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Finally, UBS Group increased their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Seven investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $593.00.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.